Zoetis IPO values Pfizer animal health business at up to $15.8bn
This article was originally published in Scrip
Executive Summary
Pfizer priced the initial public offering of 86.1 million shares of its animal health business, which will be spun out in a new company called Zoetis, at $22 to $25 per share in an amended S-1 form filed with the US Securities and Exchange Commission (SEC) on 17 January, valuing the company at about $11.8 billion at the mid-point of its price range, or $23.50 per share.
You may also be interested in...
Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Acadia’s Nuplazid Shows Nearly Three-Fold Reduction In Psychosis Relapse
Data presented at the CTAD meeting for pimavanserin in dementia-related psychosis will support an sNDA filing in 2020 for an approval that could broaden the drug’s market exponentially.
Need a specific report? 1000+ reports available
Buy Reports